• Log In
    New user? Click here to register. Have you forgotten your password?
Repository logo
  • Communities & Collections
  • All of MR
  • Log In
    New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Nantongo, Carol"

Now showing 1 - 2 of 2
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Item
    Dyslipidemia and associated factors among people living with HIV on dolutegravir-based antiretroviral therapy in central Uganda
    (SAGE Publications, 2025-10-23) Timbigamba, Flavia; Bagenda, Charles Nkubi; Sembogga, Hendry; Wasswa, Timothy; Bazibu, Faizo; Ssali, Joseph; Ssemwanga, Elastus; Mugisa, Michael Junior; Nuwagaba, Edwin; Ojuko, Samuel; Nantongo, Carol; Wafwoyo, Jesca Akoth; Musinguzi, Benson; Akiteng, Winnie; Osuwat, Lawrence Obado
    Introduction Dolutegravir (DTG)-based antiretroviral therapy (ART) use has been associated with excessive weight gain, increasing the risk of dyslipidemias such as hypercholesterolemia. We assessed the prevalence of, and associated factors with dyslipidemia among adults on DTG-based ART. Materials and methods We conducted a cross-sectional study among 281 systematically sampled adults on DTG-based ART for ≥ 6 months at Kira Health Centre IV, Wakiso District, Central Uganda. Data were collected through structured questionnaires, medical record reviews, anthropometric measurements, and laboratory biomarker analysis. Logistic regression was used to determine associated factors, and the predictive performance of obesity indices was evaluated using receiver operating characteristic (ROC) curve analysis. Results The prevalence of dyslipidemia was 44.1% 95% CI: 38.4%–50.0%. Low high-density lipoprotein (HDL) cholesterol was the most common abnormality, affecting 39.9% of participants, followed by elevated total cholesterol at 5.7% [95% CI: 3.51–9.11] and elevated low-density lipoprotein (LDL) cholesterol at 5.0%. High waist circumference (WC) was significantly associated with dyslipidemia; (aPR: 1.93, 95% CI: 1.15–3.24, p = .013), and demonstrated a significant ability to predict dyslipidemia with area under the curve (AUC) of 0.577 [95% CI: 0.511–0.644]. The AUC for WC in predicting hypercholesterolemia, elevated LDL-C, and low HDL-C were 0.702 (95% CI: 0.547–0.857), 0.729(95% CI: 0.590–0.867), and 0.548 (95% CI: 0.481–0.616) respectively. Conclusion Dyslipidemia is prevalent among adults on DTG-based ART, and is potentially associated with high WC.
  • Loading...
    Thumbnail Image
    Item
    Total cholesterol/high-density lipoprotein cholesterol ratio is a significant predictor of metabolic syndrome among people on dolutegravir-based antiretroviral therapy: A cross-sectional study in southwestern Uganda
    (Sage, 2025-08-29) Bagenda, Charles Nkubi; Nantongo, Carol; Ssemwanga, Elastus; Mugisa, Michael Junior; Ojuko, Samuel; Sempijja, Fred; Nzaramba, Daniel; Kiconco, Ritah; Ssedyabane, Frank; Musinguzi, Benson; Akiteng, Winnie; Tusubira, Deusdedit; Osuwat, Lawrence Obado; Rugera, Simon Peter
    Objective: The total cholesterol/high-density lipoprotein cholesterol ratio is a predictor of nonalcoholic fatty liver disease—a hepatic manifestation of metabolic syndrome. This study investigated the association between total cholesterol/high-density lipoprotein cholesterol ratio and metabolic syndrome among people living with human immunodeficiency virus on dolutegravir-based antiretroviral therapy in southwestern Uganda. Methods: We conducted a secondary analysis of data obtained from a cross-sectional study of 377 adults who had been on dolutegravir-based antiretroviral therapy for at least 1 year at Ruhoko Health Centre IV, southwestern Uganda. Results: The median total cholesterol/high-density lipoprotein cholesterol ratio was significantly higher in individuals with metabolic syndrome (3.92) than in those without (2.96, p < 0.001). A statistically significant association was observed between high total cholesterol/high-density lipoprotein cholesterol ratio and metabolic syndrome (adjusted odds ratios: 2.06, 95% confidence interval: 1.08–3.91, p 1⁄4 0.028). The total cholesterol/high-density lipoprotein cholesterol ratio at an optimal cutoff of 3.30 had a significant ability (area under the curve 1⁄4 0.696, 95% confidence interval: 0.642–0.750) to differentiate participants with metabolic syndrome from those without at a sensitivity of 73% and specificity of 60%. Conclusion: The total cholesterol/high-density lipoprotein cholesterol ratio is a significant pre-dictor of metabolic syndrome and serves as a potential blood-based biomarker.

University Repository :: copyright © 2025 Muni University

  • Library Website
  • Library OPAC
  • Library Ebooks (Intranet)
  • Powered by DSpace